Piramal, Ajinomoto team on ADC Development and Manufacturing 

Collaboration of Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd, and Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical manufacturing services and platform technologies. 

Through this collaboration, the company aims to provide our customers with streamlined pathways and access to deep ADC expertise to advance high-quality programs from early development through commercial manufacturing. 

Piramal refers applicable customers seeking ADC manufacturing technology to Aji Bio-Pharma and AJICAP, where customers can use AJICAP technology as a potential CDMO for manufacturing products using AJICAP technology, supporting their programs across development and manufacturing. 

According to Towards Healthcare, the ADC contract manufacturing market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 7.68 billion in 2026 to approximately USD 22.88 billion by 2035, representing a compound annual growth rate (CAGR) of 12.9% from 2026 to 2035. Growth is driven by the increasing rise in ADC drug approvals, which is contributing to the global prevalence of cancer, and the need for targeted therapies like ADCs is driving the demand for ADCs in cancer treatment. The ADC Contract Manufacturing Market is anticipated to grow significantly in the coming decade, driven by the rich pipeline of ADC therapeutics and the complexities associated with their manufacturing.  

About Piramal Pharma Solution 

It provides end-to-end solutions that cater to the diverse needs of its clients in the pharmaceutical sector. With a focus on innovation, quality, and patient outcomes, PPS continues to play a significant role in advancing healthcare solutions globally. 

The company is dedicated to patient-centricity, ensuring that its operations align with the needs of patients and healthcare providers. This commitment is reflected in its extensive experience and success in developing and manufacturing complex molecules and formulations. 

CEO, Piramal Global Pharma, Peter DeYoung said, " We are excited to collaborate with Ajinomoto Bio-Pharma Services and enhance our ADC platform by offering manufacturing support for AJICAP-based products.” 

A recent report by Towards Healthcare highlights that the ADC contract manufacturing market is witnessing growth due to the growth is primarily due to the approval of new ADC therapies and the robust pipeline of drugs in development, increasing demand for innovative cancer therapies. The high cost of developing and manufacturing ADCs, coupled with the complex and specialized processes involved, has led to a significant reliance on Contract Development and Manufacturing Organizations (CDMOs).